Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000475

Drug Information
NameMinaprine
SynonymsAC1L1HMV; Spectrum4_000418; D05039; M3157_SIGMA; IDI1_000063; Minaprina [INN-Spanish]; BSPBio_002909; NCGC00016795-01; KBioSS_001814; Prestwick1_000066; BPBio1_000277; Minaprinum; Spectrum5_001593; BRD-K02867583-300-05-5; CB 30038; MolPort-003-958-699; CHEBI:51038; CHEMBL278819; Cantor; DB00805; CAS-25953-17-7; SPBio_001454; 4-Methyl-3-(2-morpholinoethylamino)-6-phenylpyridazin; AR-1G3866; 4-methyl-N-(2-morpholin-4-ylethyl)-6-phenylpyridazin-3-amine; 25905-77-5; KBio2_001814; KBioGR_000716; EINECS 247-329-8; AB00053599; KBio3_002409; KBio2_004382; Spectrum2_001407; Spectrum3_001445; SPBio_002172; Cantor (TN); DivK1c_000063; Prestwick0_000066; CID4199; NINDS_000063; Minaprina; Brantur; L001202; Minaprine dihydrochloride; Prestwick3_000066; N-(4-Methyl-6-phenyl-3-pyridazinyl)-4-morpholineethanamine; Minaprinum [INN-Latin]; 25953-17-7 (di-hydrochloride); KBio2_006950; Minaprine (USAN/INN); KBio1_000063; Spectrum_001334; M3157_FLUKA; BSPBio_000251; Prestwick2_000066; minaprine; Minaprine [USAN:BAN:INN]; 4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)-; ZINC19796082; 4-(2-((4-Methyl-6-phenyl-3-pyridazinyl)amino)ethyl)morpholine; AC1Q4YHU; AGR 1240; LS-92883; 3-(morpholinoethyl)amino-4-methyl-6-phenylpyridazine; NCGC00016795-02
IndicationDepression
[ICD9: 311   ICD10: F32]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C17H22N4O/c1-14-13-16(15-5-3-2-4-6-15)19-20-17(14)18-7-8-21-9-
11-22-12-10-21/h2-6,13H,7-12H2,1H3,(H,18,20)
InChIKeyLDMWSLGGVTVJPG-UHFFFAOYSA-N
Canonical SMILESCC1=CC(=NN=C1NCCN2CCOCC2)C3=CC=CC=C3    
Therapeutic ClassAntidepressive Agents
CAS NumberCAS 25905-77-5
FormulaC17H22N4O
PubChem Compound IDCID 4199.
PubChem Substance IDSID 213627.
ChEBI51038;
SuperDrug ATC IDN06AX07
SuperDrug CAS ID025905775;
Target5-hydroxytryptamine 2B receptorAntagonist[2][3]
Ref 1Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease. Expert Opin Investig Drugs. 2006 Jan;15(1):1-12. To Reference
Ref 2Mini Rev Med Chem. 2007 Nov;7(11):1108-19.Privileged structures: a useful concept for the rational design of new lead drug candidates. To Reference
Ref 3Protective effect of minaprine against the abnormal changes of 2-deoxyglucose uptake by rat hippocampal slices induced by hypoxia/hypoglycemia. Jpn J Pharmacol. 1992 Sep;60(1):33-8. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543